Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018

作者
Ciara A. Murray,Clare D’Arcy,Giuseppe Gullo,Louise Flanagan,Cecily Quinn
出处
期刊:Archives of Pathology & Laboratory Medicine [American Medical Association]
卷期号:143 (4): 412-413 被引量:7
标识
DOI:10.5858/arpa.2018-0905-le
摘要

To the Editor.—We welcome the recently published American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) clinical practice guideline focused update for human epidermal growth factor receptor 2 (HER2) testing in invasive breast carcinoma.1The 2013 ASCO/CAP guideline2 addressed concerns that the 2007 diagnostic requirements3 for HER2 positivity were too rigid, potentially excluding patients who would have been deemed eligible for targeted therapy in the initial trastuzumab trial.4,5 In addition to reducing the threshold for positive and equivocal HER2 status on immunohistochemistry (IHC), the HER2:chromosome enumeration probe 17 (CEP17) ratio used to define a positive in situ hybridization (ISH) result decreased from ≥ 2.2 to ≥ 2 irrespective of HER2 copy number. Tumors with a ratio < 2 were positive if the copy number was ≥ 6 and equivocal if copy number was ≥ 4 and < 6.2 Recent re-evaluation of the interpretations of the HER2 fluorescent in situ hybridization (FISH) assays from Breast Cancer International Research Group clinical trials showed significant benefit from trastuzumab therapy only in patients with a tumor HER2:CEP17 ratio ≥ 2.0 and copy number ≥ 4.0.6 This profile is considered definitively positive in the 2018 update, which incorporates IHC and additional ISH cell counting to define HER2 status in the less common ISH patterns. Specifically, tumors with ratio ≥ 2.0 and copy number < 4.0 are negative unless IHC 3+. Tumors with ratio < 2.0 and copy number ≥ 6.0 are positive if IHC 3+ or IHC 2+ and the ISH result is confirmed by an additional observer. Equivocal cases with ratio < 2.0 and copy number ≥ 4.0 and < 6.0 are negative unless IHC 3+.1This study evaluated the impact of the changes in HER2 status categorization on a series of 1,044 tumors with equivocal HER2 IHC further tested using reflexive dual-probe HER2:CEP17 FISH methodology at St Vincent's University Hospital, Dublin, from 2014 to 2016. Specimens came from breast core biopsies, surgical excisions, and biopsies of metastatic sites and were identified from the histopathology database at St Vincent's University Hospital. The methods used were described previously by our group.7 FISH results were categorized using the scoring thresholds and definitions of the 2007, 2013, and 2018 ASCO/CAP guidelines,1–3 and the final diagnostic categories were compared.The application of the 2007 guideline for FISH-tested tumors revealed 112 (10.7%) positive, 814 (78.0%) negative, and 118 (11.3%) borderline (equivocal) tumors. Classification of the same tumors by the 2013 guideline elicited 182 (17.4%) positive, 824 (79.0%) negative, and 38 (3.6%) equivocal tumors. Categorization according to the 2018 update resulted in 107 (10.2%) positive, 937 (89.8%) negative, and no equivocal tumors. The relative distribution of HER2 FISH results is summarized in the Table.In this series of FISH-tested tumors, we observed an increase in positive tumors (17.4% v 10.7%) using 2013 criteria compared with 2007 criteria, identifying an additional 70 patients (6.7%) who met the eligibility criteria for HER2-targeted therapy.2,3 Applying the 2018 guideline,1 75 tumors (7.1% of the series) defined as positive applying 2013 criteria were recategorized as negative because of copy number < 4 with a ratio ≥ 2. These tumors were equivocal (45) and positive (30) when applying the 2007 guideline. The percentage of FISH-positive tumors (10.2%) according to 2018 criteria is similar to that observed using 2007 standards (10.7%), with an altered composition. The 107 tumors that were positive according to 2018 were positive (83), equivocal (23), and negative (1) using the 2007 guideline. These tumors were all positive according to 2013 criteria. Thirty patients (2.9%) with tumors positive by both 2007 and 2013 guidelines would no longer be candidates for HER2-targeted treatment. The recommendations regarding HER2 copy number ≥ 6 and HER2:CEP17 < 2.0 minimally affects our cohort, with only one tumor meeting this criterion for positivity, similar to other studies.8,9Our experience suggests that the 2018 update heralds a potential change in therapeutic options for a significant number of patients, with 2.9% of FISH-positive tumors according to 2007 and 2013 guidelines now categorized as HER2 negative.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
精明依云发布了新的文献求助10
刚刚
专一的弱完成签到,获得积分10
刚刚
刚刚
希望天下0贩的0的应助被Johnny采纳,获得10
刚刚
1秒前
Heven88发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
风中小丸子完成签到,获得积分10
1秒前
2秒前
可爱的函函的应助被paopao采纳,获得10
2秒前
2秒前
molihuakai的应助被ZZXX采纳,获得10
2秒前
Aurora完成签到 ,获得积分10
2秒前
小队昵称完成签到,获得积分10
3秒前
伽玛伽玛完成签到 ,获得积分10
4秒前
starcraftfan完成签到,获得积分10
5秒前
5秒前
xdy发布了新的文献求助10
5秒前
Walker完成签到,获得积分10
5秒前
星空完成签到,获得积分10
5秒前
贾贡献的应助被诚心的万宝路采纳,获得10
5秒前
rslysywd发布了新的文献求助10
5秒前
大气的杨完成签到 ,获得积分10
6秒前
雨文发布了新的文献求助10
6秒前
oooaaa发布了新的文献求助10
7秒前
精明依云发布了新的文献求助10
8秒前
大君完成签到,获得积分10
10秒前
百步穿小杨完成签到,获得积分10
10秒前
10秒前
10秒前
阿金发布了新的文献求助10
10秒前
11秒前
tuanzi完成签到,获得积分10
11秒前
11秒前
Vincy完成签到 ,获得积分10
11秒前
12秒前
贝贝贝发布了新的文献求助10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621